熱門資訊> 正文
Entera Bio宣布在6月13日至16日的内分泌学会年度会议上展示支持其口服肽管道的新数据
2026-05-28 20:54
- Abstract Title: Transforming Anabolic Treatments for Osteoporosis: New Clinical Data Supports a Single EB613 Tablet [Oral PTH(1-34)] as the Final Candidate for a Phase 3 Study
Session Title: Late-Breaking Oral Abstract/Rapid-Fire II
Session Date/Time: Sunday, June 14, 2026, 3:30 – 4:15 PM CT
- Abstract Title: Pre-Clinical Results for EB612: First-in-Class Oral Long-Acting PTH(1-34) Analog as Hormone Replacement Tablet for Patients with Hypoparathyroidism
Session Date/Time: Monday, June 15, 2026, 12:00 – 1:30 PM CT
- Abstract Title: EB618, First-in-Class Oral Tablet of Dual GLP-1/Glucagon Receptor Agonist for Patients with Obesity and Metabolic Disorders: Results from PK-PD Study in Non-Human Primates
Session Date/Time: Saturday, June 13, 2026, 12:15 – 1:45 PM CT
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。